2019 Results
Sort By:
Published on January 22, 2024
On the heels of success for its new heart drug (acoramidis) in Phase III, BridgeBio Pharma has raised up to $1.2B from Blue Owl Capital and Canada Pension Plan Investment Board (CPP Investments). BridgeBio expects acoramidis will launch soon and become the “potential backbone of therapy for transthyretin amyloid cardiomyopathy…
Published on February 23, 2022
A $700M research institute will be launched in Boston’s Fort Point section by Eli Lilly as part of its strategy to advance RNA therapeutics and other genetic medicines, which now account for a significant amount of the company’s therapeutic portfolio. Researchers at the Institute will work with colleagues in New…
Published on January 26, 2024
Cambridge-based Sano Genetics has raised $11.4M in a new funding round to drive its clinical trials software platform in precision medicine. The latest funding was led by early-stage investors Plural with the participation of venture capitalists MMC Ventures, which led its Series A round, as well as existing contributors Episode…
Published on October 2, 2023
New data presented Sunday at the American Society for Radiation Oncology (ASTRO) Annual Meeting shows that precision medicine navigators (PMNs) increased the rate of genetic testing in Black prostate cancer patients six-fold. The findings have the potential to significantly reduce the health inequities and improve health outcomes for black patients.…
Published on March 31, 2023
Researchers have created an open-access resource of genetic information and an algorithm that together could provide valuable tools for personalized medicine. EN-TEx, outlined in the journal Cell, is the world’s most extensive catalog of genetic mutations known as allele-specific variants. It deeply profiles approximately 30 overlapping tissues from the same…
Published on July 22, 2022
Commercial-stage biopharmaceutical company BridgeBio Pharma and Baylor College of Medicine announced the two will enter an academic collaboration that will seek to translate research findings into new therapies to treat genetic diseases. BridgeBio has adopted a strategy of identifying cutting-edge research in academia and finding way to leverage this information…
Published on April 26, 2022
American-Swiss health tech firm SOPHiA Genetics announced it has analyzed one million genomic profiles from around the world using its cloud-based data-driven medicine (DDM) platform. The company was founded in Lausanne in 2011 by Jurgi Camblong, Pierre Hutter, and Lars Steinmetz as a spin out from the École Polytechnique Fédérale…
Published on November 18, 2021
Chroma Medicine, a new Cambridge, Massachusetts startup, came out of stealth mode and officially launched this week with $125M in Series A financing to develop the therapeutic potential of epigenetic editing. The company has a team of well-known and experienced scientific founders including Beam Therapeutics founder and Broad Institute professor…
Published on March 9, 2021
Foundation Medicine and genetics services provider InformedDNA, announced today a collaboration for patient referral to InformedDNA for genetic counseling services and to provide patients with advice on confirmatory genetic testing based on the results of an initial tumor test from Foundation Medicine. Genetic counseling and follow up germline testing of…
Published on May 11, 2020
Regeneron Pharmaceuticals and the Colorado Center for Personalized Medicine (CCPM) announced today a precision medicine research collaboration that will tap into 450,000 DNA samples and corresponding health records from de-identified, consented patient participants in the UCHealth system. Under the deal, the Regeneron Genetics Center (RGC) will sequence these samples, to…
Published on May 6, 2020
Two researchers at Canada’s McMaster University contend that the promise of precision medicine implied nearly 20 years ago with the completion of the Human Genome Project has not fully materialized because the full sophistication of the genetic blueprint has a more complex and far-reaching influence on human health than scientists…
Published on August 2, 2019
The nation’s largest private health insurer, UnitedHealthcare, announced August 1 that it will cover testing that will allow physicians to match their patients to anti-depressants most likely to work for them based on their genetic profiles. The new coverage policy, which also includes multi-gene panel testing for antipsychotic medications, goes…
Published on October 4, 2017
Precision for Medicine has acquired Epiontis for an undisclosed price, in a deal designed to add epigenetic expertise and an expanded global presence to the buyer’s precision medicine capabilities. Berlin-based Epiontis is a specialty laboratory that has developed a novel, patent-protected epigenetic platform, through which it offers an immune cell…
Published on February 10, 2017
Jun Wang, Ph.D., CEO of iCarbonX, a China-based artificial intelligence (AI) start-up, has announced the launch of a new digital life alliance that will aim to improve health and wellness on a grand scale. The alliance of seven omics, AI, and bio companies will work together as an “ecosystem,” Wang…
Published on July 22, 2016
In an effort to standardize terminology that characterizes pharmacogenetic functions and phenotypes—toward the ultimate goal of implementing clinical pharmacogenetics as a common part of precision medicine—a study led by researchers at St. Jude Children's Research Hospital has tackled the language barrier that is often an obstacle in enhancing medication safety…